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Abstract The somatic isoform of angiotensin-converting en-
zyme (ACE) consists of two homologous domains (N- and C-do-
mains), each bearing a catalytic site. We have used the two-
domain ACE form and its individual domains to compare char-
acteristics of di¡erent domains and to probe mutual functioning
of the two active sites within a bovine ACE molecule. The sub-
strate Cbz-Phe-His-Leu (N-carbobenzoxy-L-phenylalanyl-L-his-
tidyl-L-leucine; from the panel of seven) was hydrolyzed faster
by the N-domain, the substrates FA-Phe-Gly-Gly (N-(3-[2-
furyl]acryloyl)-L-phenylalanyl-glycyl-glycine) and Hip-His-Leu
(N-benzoyl-glycyl-L-histidyl-L-leucine) were hydrolyzed by both
domains with equal rates, while other substrates were preferen-
tially hydrolyzed by the C-domain. The inhibitor captopril
((2S)-1-(3-mercapto-2-methylpropionyl)-L-proline) bound to the
N-domain more e¡ectively than to the C-domain, whereas
lisinopril ((S)-NK-(1-carboxy-3-phenylpropyl)-L-lysyl-L-proline)
bound to equal extent with all ACE forms. However, active
site titration with lisinopril assayed by hydrolysis of FA-Phe-
Gly-Gly revealed that 1 mol of inhibitor/mol of enzyme abol-
ished the activity of either two-domain or single-domain ACE
forms, indicating that a single active site functions in bovine
somatic ACE. Neither of the kcat values obtained for somatic
enzyme was the sum of kcat values for individual domains, but in
every case the value of the catalytic constant of the hydrolysis of
the substrate by the two-domain ACE represented the mean
quantity of the values of the corresponding catalytic constants
obtained for single-domain forms. The results indicate that the
two active sites within bovine somatic ACE exhibit strong neg-
ative cooperativity.
1 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Angiotensin-converting enzyme (ACE, peptidyl dipeptidase
A, EC 3.4.15.1) is a type-I membrane-anchored glycoprotein,
a member of the gluzincins, de¢ned by a HExxH motif and a
glutamic acid residue as the third zinc ligand [1]. This enzyme
is essential for blood pressure control and water^electrolyte
homeostasis through the renin^angiotensin^aldosterone sys-
tem [2].
Two distinct ACE isoenzymes have been identi¢ed in mam-
malian tissues, the primary structure of which was determined
by molecular cloning and sequencing of the complementary
DNA [3,4]. The somatic form of ACE (1277 amino acids in
human enzyme) consists of two homologous domains (N- and
C-domains) within a single polypeptide chain, and each do-
main bears its own catalytic site [3]. The tertiary structure of
somatic ACE is still unknown.
The other ACE isoenzyme is present exclusively in testes
and is associated with mature germ cells [5]. Testicular ACE
is identical to the C-terminal half of the somatic enzyme ex-
cept for a short N-terminal sequence and thus contains only
one catalytic site [4]. The crystal structure of testicular ACE
was recently described [6].
The N-domain of ACE was also found in humans, and this
ACE form is believed to be a result of limited proteolysis of
the parent somatic form [7]. Several studies indicate that ‘the
bridge sequence’ between the two domains can be cleaved in
vitro. Native human ACE molecule was found to be suscep-
tible to endoproteinase Asp-N producing both domains of the
enzyme [8], while a variety of serine proteases were able to
cleave partially denatured ACE [9^11]. The latter approach
always results in the isolation of only the ACE N-domain
[10,11], whereas the remaining part of the molecule undergoes
denaturation and proteolytic digestion. Moreover, di¡erent
heat stabilities of the domains allow selective inactivation of
the C-domain and underlie the method of acquiring an active
N-domain with inactive C-domain within a full-length ACE
[12]. The possibilities described above suggest that the two
domains within the somatic ACE molecule are rather separate
and distinctive structures.
The two catalytic sites within the somatic ACE molecule
were long considered to function independently, as the activity
of the wild-type enzyme was found to be equal to the sum of
the activities of the N- and C-domains [13]. This observation
contradicted the fact that titration of the two-domain human
somatic ACE and the single-domain rabbit testicular ACE
with competitive inhibitor lisinopril ((S)-NK-(1-carboxy-3-phe-
nylpropyl)-L-lysyl-L-proline) and FA-Phe-Gly-Gly (N-(3-[2-
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furyl]acryloyl)-L-phenylalanyl-glycyl-glycine) as a substrate re-
vealed only a single active site in both enzyme forms [14].
These results were explained by preferential binding of both
substrate and inhibitor at the assay conditions on the C-do-
main only [14]. Further studies, however, revealed that the
activity of somatic ACE often could not be represented by a
sum of the activities of the two domains [11,15^17]. This ob-
servation led to the idea [8,17] that the two domains can no
longer be considered as totally independent. The arrangement
of the two domains within the somatic ACE molecule and the
kinetic mechanism of the mutual functioning of the two active
sites still defy description.
Here we present evidence that the two active sites within the
bovine ACE molecule are absolutely dependent, which, in
turn, implies tight proximity of the two domains within the
somatic enzyme molecule.
2. Materials and methods
2.1. Enzyme puri¢cation
Bovine lung and bovine testis ACEs were puri¢ed by lisinopril
a⁄nity chromatography as described in [18]. The N-domain of ACE
was obtained by limited proteolysis of the parent somatic ACE after
partial denaturation of the enzyme in NH4OH solution as described
in [11]. All ACE preparations were proved to be homogeneous ac-
cording to electrophoresis by the Laemmli method [19] in polyacryl-
amide gel in the presence of 0.1% SDS and L-mercaptoethanol. Pro-
teins were stained with Coomassie brilliant blue G-250. Protein
concentration was determined according to the modi¢ed Lowry meth-
od [20,21].
2.2. Inhibition of ACE activity
For all kinetic experiments, we chose nearly physiological condi-
tions, namely, pH 7.5, 150 mM NaCl, 1 WM ZnCl2. Assays with
inhibitors were performed with Cbz-Phe-His-Leu (N-carbobenzoxy-
L-phenylalanyl-L-histidyl-L-leucine) as a substrate. Because both cap-
topril ((2S)-1-(3-mercapto-2-methylpropionyl)-L-proline) and lisinopril
are competitive slow-tight binding inhibitors, the preincubation time
required to produce equilibrium between enzyme and inhibitor was
preliminarily determined [22]. Prior to the addition of substrate (100
Wl), enzyme was preincubated with inhibitors for 3 h at 37‡C in a total
volume of 1.9 ml. All ACE forms were found to be stable during this
period of time. The values of inhibition constants, Ki, were deter-
mined at ¢ve substrate concentrations within 0.5^3 Km ; the enzyme
concentration in the reaction medium was equal to the Ki value de-
termined in the preliminary experiment; the inhibitor concentration
was varied from 0.5 to 10 [E]0. Apparent ACE inhibition constants,
Kappi , were determined by linearization of the data in Henderson co-
ordinates [23], [I]0/(13vi/v0) versus v0/vi, where [I]0 is the total inhib-
itor concentration and v0 and vi are the initial rates in the absence and
in the presence of the inhibitor. The true values of the inhibition
constants, Ki, were calculated by graphical extrapolation of K
app
i to
[S]0 = 0.
2.3. Kinetic characterization
Stoichiometric titration of ACE active molecules was performed
with speci¢c competitive inhibitor lisinopril as in [11]. The rates of
catalytic hydrolysis of FA-containing substrates were monitored spec-
trophotometrically by the method of [24]. The substrates FA-Phe-Phe-
Arg (N-(3-[2-furyl]acryloyl)-L-phenylalanyl-L-phenylalanyl-L-arginine),
FA-Phe-Ala-Lys (N-(3-[2-furyl]acryloyl)-L-phenylalanyl-L-alanyl-L-ly-
sine), Hip-His-Leu (N-benzoyl-glycyl-L-histidyl-L-leucine), and Cbz-
Phe-His-Leu were initially dissolved in methanol; the ¢nal methanol
concentration in the reaction medium was 5%. Hip-His-Leu and Cbz-
Phe-His-Leu hydrolyses were followed £uorimetrically by the release
of His-Leu, which was derivatized with o-phthalaldehyde [25]. Initial
rates were measured during the ¢rst 5% of substrate hydrolysis. The
kinetic constants Km and kcat were calculated by the Lineweaver^Burk
analysis from at least three independent experiments. The standard
deviations of the Km and kcat values were less than 10%.
3. Results
3.1. Inhibition of ACE activity
Cbz-Phe-His-Leu hydrolysis by the two-domain and single-
domain ACE forms was inhibited in a dose-dependent manner
by the speci¢c competitive ACE inhibitors, lisinopril and cap-
topril. The true values of the inhibition constants Ki are pre-
sented in Table 1. Previously [22], we have shown that the Ki
values obtained for testicular and somatic bovine ACEs do
not depend on the nature of the tripeptide substrate. The data
of Table 1 indicate that captopril preferably binds to the
N-domain of bovine ACE while lisinopril equally inhibits all
ACE forms.
3.2. Active site titration
Under conditions of [E]0, [I]0EKi, the reaction
Eþ I1EI
is driven predominantly to the right, i.e. to the formation of
the enzyme^inhibitor complex. The linear parts of the plots of
residual activity versus [I]0 extrapolated to the x-axis give
intersection points representing moles of the inhibitor per
mol of ACE required to abolish enzymatic activity [26]. We
titrated the number of active sites in three ACEs with lisino-
pril, the inhibitor with equal inhibitory potency towards sin-
gle-domain forms (Table 1). The results (Fig. 1) indicate that
for the two-domain somatic ACE and for both single-domain
ACE forms, binding of 1 mol of lisinopril per 1 mol ACE was
su⁄cient to block FA-Phe-Gly-Gly-hydrolyzing activity, sug-
gesting that all three bovine ACE forms reveal one active site
per molecule. Moreover, inhibition with lisinopril of Cbz-Phe-
His-Leu-hydrolyzing activity also demonstrated that only one
equivalent of the inhibitor was necessary to abolish the activ-
ity of all ACE forms (data not shown).
3.3. Kinetic parameters of the hydrolysis of synthetic tripeptide
substrates
Kinetic parameters of the hydrolysis of di¡erent tripeptide
substrates by the three bovine ACE forms are presented in
Table 2. Apparent Km values for the hydrolysis of all sub-
strates appeared to be similar for the three ACE forms, sug-
gesting similar a⁄nities of the two domains for these sub-
strates. However, the comparison of kcat values revealed the
di¡erence between ACE domains. Amongst the seven tripep-
tides surveyed, only Cbz-Phe-His-Leu was preferentially hy-
drolyzed by the N-domain, whereas FA-Phe-Ala-Ala (N-(3-
[2-furyl]acryloyl)-L-phenylalanyl-L-alanyl-L-alanine), FA-Phe-
Ala-Lys, FA-Phe-Ala-Pro (N-(3-[2-furyl]acryloyl)-L-phenyl-
alanyl-L-alanyl-L-proline), and FA-Phe-Phe-Arg were hydro-
lyzed faster by testicular ACE (C-domain). Both single-do-
main forms exhibit equal activity towards the substrates
Hip-His-Leu and FA-Phe-Gly-Gly.
Table 1
Inhibitor-binding properties of the three forms of bovine ACE
Inhibitor Enzyme Ki (M)
Somatic ACE N-domain Testicular ACE
Lisinopril (1.8S 0.2)U10310 (2.0S 0.1)U10310 (1.2S 0.2)U10310
Captopril (6.0S 0.5)U10310 (5.0S 0.2)U10310 (9.1S 0.9)U1039
Conditions: 50 mM HEPES, pH 7.5, 150 mM NaCl, 1 WM ZnCl2,
37‡C. Substrate, Cbz-Phe-His-Leu.
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Although both domains in somatic ACE are active, the
activity of somatic ACE never represented the sum of the
corresponding activities of the single-domain forms (Table
2). Moreover, the kcat value for the hydrolysis of any substrate
by the two-domain ACE was the mean quantity of the kcat
values for the hydrolysis of this substrate by the single-do-
main forms.
4. Discussion
The discovery that ACE possesses two active sites was
made more than a decade ago [3] ; however, the mechanism
of mutual functioning of the two active sites within the so-
matic ACE molecule is still unclear. Experiments with re-
combinant human ACE and various mutant forms with a
single active site in the hydrolysis of Hip-His-Leu, angiotensin
I, and bradykinin seemed to vindicate the hypothesis that the
two active sites in full-length ACE function totally indepen-
dently [13,15]. Recently, this hypothesis has received valuable
support by ¢ndings of selective inhibitors able to di¡erentiate
ACE active sites [27^29]. The phosphinic peptide RXP 407
totally blocked the N-domain in vitro, but e⁄cient hydrolysis
of angiotensin I by the C-domain still occurred under these
conditions [27]. This inhibitor also a¡ected the metabolism of
the negative regulator of hematopoiesis AcSDKP in mice
without notable e¡ect on angiotensin I metabolism [28]. Bra-
dykinin-potentiating peptides selectively inhibiting the C-do-
main were described recently as well [29]. However, some un-
certainty concerning the independence of ACE active sites still
remains. The experiments with substance P and LH-RH as
substrates did not comply with the scheme for full indepen-
dence of the domains [15]. The data on the hydrolysis of
angiotensin I and FA-Phe-Gly-Gly allowed the authors of
[8] to conclude that the two domains may not function inde-
pendently, and a thorough study of the hydrolysis of brady-
kinin-related peptides by recombinant wild-type ACE and its
full-length mutants revealed that the two domains of ACE do
not operate independently but may cooperate or coordinate
[17].
In these studies we used, besides puri¢ed bovine somatic
and testicular ACEs, puri¢ed bovine individual N-domain
obtained by limited proteolysis of the parent somatic form.
Fig. 1. Stoichiometric titration of active sites in ACE preparations
with lisinopril. a: Somatic ACE; b: N-domain; c: testicular ACE
(C-domain). Conditions: ACE solution (39 nM) in 50 mM HEPES-
bu¡er, pH 7.5, containing 150 mM NaCl, 1 WM ZnCl2, was incuba-
ted with 0^2.5 equiv. of lisinopril at 25‡C for 30 min in 980 Wl. Re-
sidual enzyme activities were then determined by adding 20 Wl of
5 mM FA-Phe-Gly-Gly in the same bu¡er and measuring the initial
rates of hydrolysis.
Table 2
Kinetic parameters for substrate hydrolysis by the three bovine
ACE forms
Somatic ACE N-domain Testicular ACE
FA-Phe-Gly-Gly
kcat (s31) 280S 16a 279S10a 260S14
Km (mM) 0.70S 0.06a 1.40S0.02a 0.50S0.02
Hip-His-Leu
kcat (s31) 12S 1a 12S1a 12S1
Km (mM) 0.90S 0.10a 0.50S0.05a 0.60S0.03
Cbz-Phe-His-Leu
kcat (s31) 58S 5a 122S10a 19S2
Km (mM) 0.25S 0.02a 0.15S0.02a 0.13S0.02
FA-Phe-Ala-Ala
kcat (s31) 108S 11a 35S3a 178S15
Km (mM) 0.05S 0.01a 0.05S0.02a 0.05S0.01
FA-Phe-Ala-Lys
kcat (s31) 54S 2 35S3 85S7
Km (mM) 0.15S 0.02 0.14S0.01 0.17S0.02
FA-Phe-Ala-Pro
kcat (s31) 30S 3 8S1 45S1
Km (mM) 0.008S 0.003 0.008S0.003 0.005S0.002
FA-Phe-Phe-Arg
kcat (s31) 60S 5a 45S4a 76S8
Km (mM) 0.05S 0.01a 0.05S0.01a 0.12S0.02
Conditions: 0.05 M HEPES, pH 7.5, 0.15 M NaCl, 1 WM ZnCl2,
25‡C.
aFrom [11].
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Bovine somatic ACE has 84% overall homology in amino acid
sequence with the human somatic enzyme [30]. The homology
between the N-domains of bovine and human ACEs is 89%,
while the homology between the C-domains of these enzymes
is 82%.
Numerous previous studies of the recombinant variants of
human ACE, testicular rabbit ACE (highly homologous to
the C-domain of human ACE), and individual N-domain of
human enzyme obtained from ileal £uid or by limited proteol-
ysis of the somatic form demonstrated that, as a whole, the
enzymatic properties of naturally occurring and recombinant
individual domains are similar [7,10] and coincide with the
properties of full-length recombinant ACEs with critical mu-
tation in one of two domains [13,15,31]. Thus, the usage of
di¡erent ACE forms allows us to compare catalytic properties
of the individual domains of the enzyme and, furthermore, to
assess the mutual functioning of the two active sites within the
somatic ACE molecule.
We showed similar a⁄nities of the two bovine ACE do-
mains to the tripeptide substrates and to lisinopril at 150
mM NaCl (Tables 1 and 2). The latter observation is in con-
trast with earlier data for human recombinant enzyme [31],
for which lisinopril was found to inhibit preferably the
C-domain, but coincides with more recent data for the same
enzyme [32]. The potency of the inhibitor captopril was 10
times more pronounced towards the bovine N-domain (Table
1). For comparison, captopril inhibited only slightly better the
activity of the N-domain of human ACE with Hip-His-Leu as
a substrate at 300 mM NaCl and inhibited much better the
activity of the N-domain at low Cl3 concentration (20 mM)
[31], while this inhibitor was reported to be 16 times more
e⁄cient for blocking the activity of the human N-domain,
than the C-domain, with N-Ac-Ser-Asp-Lys-Pro as a sub-
strate at 50 mM NaCl [16].
Two active sites of bovine ACE demonstrate equal catalytic
constants in the hydrolysis of the substrates Hip-His-Leu and
FA-Phe-Gly-Gly. The substrate Cbz-Phe-His-Leu is hydro-
lyzed faster on the N-domain, while other tripeptide sub-
strates are hydrolyzed faster on the C-domain (Table 2).
These data do not correspond to those for human ACE, for
which Hip-His-Leu is preferentially hydrolyzed on the C-do-
main [13], while Cbz-Phe-His-Leu is hydrolyzed on both do-
mains with equal rates [33]. Thus, despite overall protein ho-
mology, bovine and human ACEs exhibit species substrate
speci¢city.
Active site titration with lisinopril assayed by hydrolysis of
FA-Phe-Gly-Gly revealed that 1 mol of inhibitor/mol of en-
zyme abolished the activity of either two-domain or single-
domain bovine ACE forms, indicating that only one active
site functions in somatic ACE. These data are in agreement
with the previous observation that both somatic human ACE
and testicular rabbit ACE [14] exhibited one active site per
molecule upon titration with lisinopril. These results were ex-
plained before by preferential binding of both inhibitor and
substrate on the C-domain of the somatic enzyme [14]. How-
ever, both active sites in bovine ACE possess equal a⁄nity to
lisinopril and possess equal catalytic properties with respect to
the hydrolysis of FA-Phe-Gly-Gly (Tables 1 and 2), suggest-
ing that either one of the active sites is ‘silent’ in bovine ACE
or binding of the inhibitor to one active site prevents hydro-
lysis of the substrate at another site. The existence of a ‘silent’
active site is highly unlikely as bovine ACE is highly homol-
ogous to the human enzyme, which has two functional active
sites. Moreover, in a previous £uorescence polarization study
[34] of di¡erent bovine ACE forms we showed the presence of
two populations of complexes between somatic enzyme and
£uorescent-labeled lisinopril in conditions of a signi¢cant lack
of the inhibitor; that was attributed to the formation of com-
plexes of labeled lisinopril with di¡erent ACE domains.
The analysis of kinetic parameters of the hydrolysis of the
substrates by di¡erent ACE forms con¢rms the existence of a
strong negative cooperativity between the two bovine ACE
domains. If the values of Km were almost similar for all
ACE forms, the values of kcat markedly di¡ered, and that
allows assessing the mutual functioning of the two active sites
within the somatic enzyme. The kcat value of the hydrolysis of
de¢nite substrate by somatic enzyme by no means either rep-
resented the sum of corresponding kcat values for individual
domains or was higher than the value obtained for the more
active domain. Moreover, the kcat value for the two-domain
ACE was always the average quantity of the kcat values for
single-domain forms.
There are three simple schemes for the mutual functioning
of the two active sites within a single enzyme:
A. Active sites within a two-domain enzyme function as two
separate independent enzymes. Then, the value of the cat-
alytic constant, kcat, for the whole enzyme will be repre-
sented by the sum of the kcat values for individual sites.
B. Only one active site of the two functions at any moment.
Then, the kinetic constants for the whole enzyme are de-
rived from combination of kinetic constants for individual
sites:
kcat ¼ ðkcat;1=Km;1 þ kcat;2=Km;2Þ=ðKm;1 þ Km;2Þ
Km ¼ Km;1UKm;2=ðKm;1 þ Km;2Þ
C. The enzyme can bind another substrate molecule on the
second active site when the ¢rst site is already occupied,
but the resulting complex SES is non-productive. There-
fore, the Lineweaver^Burk plot can be expected to decline
at high substrate concentration due to enzyme inhibition,
and the maximum rate of enzymatic hydrolysis should be
observed at substrate concentration [S] = (Km;1UKm;2)1=2.
In the present case, variant A is immediately eliminated as
we have already noted. Variant C should be eliminated as
well, as any declining from the Lineweaver^Burk plot for
FA-Phe-Phe-Arg that we have observed elsewhere [22] was
marked for both somatic and single-domain forms. The de-
scription of mechanism B can be further simpli¢ed, as the Km
values of the hydrolysis of any substrate by single-domain
ACE forms appeared to be virtually identical. Hence, the
kcat value for the whole enzyme can be represented as a
mean quantity of the values of kcat for individual sites:
kcat ¼ ðkcat;1 þ kcat;2Þ=2
Our results demonstrate that the values of kcat of the hy-
drolysis of tripeptide substrates by three bovine ACE forms
perfectly coincide with mechanism B. Thus, while both sites in
bovine two-domain ACE are active, random binding of the
substrate molecule to one of the active sites prohibits or dra-
matically decreases binding of another substrate molecule to
the second site.
Titration of a single active site within two-domain ACE
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with inhibitor lisinopril and FA-Phe-Gly-Gly (or Cbz-Phe-
His-Leu) as a substrate is also easily explained by mechanism
B. In this case, the inhibitor randomly binds to any active site
in somatic ACE, but the second active site fails to bind the
substrate and, therefore, to reveal enzymatic activity.
The results demonstrate strong negative cooperativity be-
tween the two active sites within bovine somatic ACE, which
suggests tight proximity of the two domains within the ACE
molecule. However, a full understanding of the precise ar-
rangement of the domains and the nature of the interactions
between domains waits for the de¢nition of the three-dimen-
sional structure of the somatic enzyme.
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